RxDoctor Payments Data

James Watkins, MD

Family Medicine · Houma, LANPI 1740546381

Payments from drug & device makers

$11,352in general payments, 2019–2025

Across 744 payments — averaging $15.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$971
  • GSK$843
  • Lilly USA, LLC$820
  • Novo Nordisk$617
  • Boehringer Ingelheim$580
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$11,340100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)137$1,891
Pfizer60$971
GSK58$843
Lilly USA, LLC57$820
Novo Nordisk43$617
Boehringer Ingelheim45$580
AstraZeneca15$440
Amgen23$410
Merck30$389
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC30$353
Antares Pharma, Inc.16$337
Kowa Pharmaceuticals America, Inc.23$320
Esperion Therapeutics, Inc.18$287
Johnson & Johnson15$211
Amarin Pharma, Inc.13$202
Mylan Specialty L.p.13$200
Sunovion Pharmaceuticals Inc.12$185
Exact Sciences8$153
Bayer8$132
Jazz Pharmaceuticals Inc.6$129
Astellas Pharma US Inc7$119
Abbott6$118
Phathom Pharmaceuticals, Inc.8$115
Otsuka America Pharmaceutical, Inc.6$110
Sanofi-aventis U.S. LLC7$109
E.r. Squibb & Sons, L.L.C.7$102
Teva Pharmaceuticals USA, Inc.7$95
Corium, LLC5$86
Takeda Pharmaceuticals U.S.A., Inc.4$72
Halozyme Inc3$71
Azurity Pharmaceuticals, Inc.4$69
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$66
Eisai Inc.4$62
Smith+Nephew4$61
Arbor Pharmaceuticals, Inc.4$56
Vanda Pharmaceuticals Inc.2$44
Novartis3$44
Supernus Pharmaceuticals, Inc.2$36
Biohaven Pharmaceutical Holding Company Ltd.2$33
Gilead2$30
Sumitomo Pharma America, Inc.2$30
Shire North American Group Inc2$27
Lundbeck LLC2$26
Viatris Specialty LLC1$26
Axsome Therapeutics, Inc.1$22
Bausch Health US, LLC1$21
Optinose US, Inc.1$21
Daiichi Sankyo Inc.1$19
Shield Therapeutics Inc1$18
Currax Pharmaceuticals LLC1$18
Seqirus USA Inc1$17
Inspire Medical Systems, Inc.1$16
Biohaven Pharmaceuticals, Inc.1$15
Hikma Pharmaceuticals USA1$15
Acerus Pharmaceuticals Corporation1$14
Tolmar, Inc.1$14
Clarus Therapeutics Inc.1$14
Boston Scientific1$14
Ironwood Pharmaceuticals, Inc1$13
Genentech USA, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,352 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$211,405
Medicare patients
500
Services billed
8,803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide140$164,860
JardianceEmpagliflozin236$153,868
OzempicSemaglutide128$153,512
EliquisApixaban222$97,803
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$42,618
XareltoRivaroxaban88$38,899
MyrbetriqMirabegron79$33,513
RexultiBrexpiprazole18$29,007
EntrestoSacubitril/Valsartan53$19,713
LinzessLinaclotide12$16,984
FarxigaDapagliflozin Propanediol35$16,490
TrulicityDulaglutide13$14,648
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$13,529
Repatha SureclickEvolocumab15$10,687
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog48$10,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$820$179,507153 claims
Boehringer IngelheimJardiance, Stiolto Respimat$580$161,772249 claims
Novo NordiskOzempic$617$153,512128 claims
PfizerEliquis$971$97,803222 claims
GSKTrelegy Ellipta, Anoro Ellipta$843$56,14777 claims
Johnson & JohnsonXarelto$211$38,89988 claims
Astellas Pharma US IncMyrbetriq$119$33,51379 claims
Otsuka America Pharmaceutical, Inc.Rexulti$110$29,00718 claims
NovartisEntresto$44$19,71353 claims
AbbVieLinzess$1,891$16,98412 claims
AstraZenecaFarxiga$440$16,49035 claims
Sumitomo Pharma America, Inc.Gemtesa$30$3,42714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Houma

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →